Ampio Pharmaceuticals, Inc. — TTAB Proceedings
Ampio Pharmaceuticals, Inc. is a party to 2 TTAB proceedings.
Proceedings
- Proceeding 91224304 — Oppositions, Terminated (filed 2015-10-12) against Gilead Sciences, Inc. as defendant
- Proceeding 86298066 — Extensions of Time to Oppose, Terminated (filed 2015-05-11) against Gilead Sciences, Inc. as defendant
Marks in These TTAB Matters
Recent Live Filings
- AMPIO PHARMACEUTICALS — Registered, filed 2013-08-15
Common TTAB Counterparties
- Gilead Sciences, Inc. — 2 proceedings
Recent TTAB Timeline
- 2016-03-14: 91224304 — TERMINATED involving Gilead Sciences, Inc.
- 2016-03-14: 91224304 — BD'S DECISION: DISMISSED W/O PREJUDICE involving Gilead Sciences, Inc.
- 2016-03-11: 91224304 — D RESP TO BD ORDER/INQUIRY involving Gilead Sciences, Inc.
- 2016-02-24: 91224304 — RESPONSE DUE 30 DAYS (DUE DATE) involving Gilead Sciences, Inc.
- 2016-02-19: 91224304 — WITHDRAWAL OF APPLICATION involving Gilead Sciences, Inc.
- 2016-01-25: 91224304 — EXTENSION OF TIME GRANTED involving Gilead Sciences, Inc.
- 2016-01-19: 91224304 — D'S MOT FOR EXTEN. OF TIME W/ CONSENT involving Gilead Sciences, Inc.
- 2015-11-16: 91224304 — EXTENSION OF TIME GRANTED involving Gilead Sciences, Inc.
- 2015-11-16: 91224304 — D'S MOT FOR EXTEN. OF TIME W/ CONSENT involving Gilead Sciences, Inc.
- 2015-11-10: 91224304 — TRIAL DATES REMAIN AS SET involving Gilead Sciences, Inc.
- 2015-11-04: 91224304 — SUBMITTED ON BRIEF involving Gilead Sciences, Inc.
- 2015-10-12: 91224304 — PENDING, INSTITUTED involving Gilead Sciences, Inc.
- 2015-10-12: 91224304 — NOTICE AND TRIAL DATES SENT; ANSWER DUE: involving Gilead Sciences, Inc.
- 2015-10-12: 91224304 — FILED AND FEE involving Gilead Sciences, Inc.
- 2015-08-10: 86298066 — EXTENSION OF TIME GRANTED involving Gilead Sciences, Inc.
- 2015-08-10: 86298066 — INCOMING - EXT TIME TO OPPOSE FILED involving Gilead Sciences, Inc.
- 2015-05-11: 86298066 — EXTENSION OF TIME GRANTED involving Gilead Sciences, Inc.
- 2015-05-11: 86298066 — INCOMING - EXT TIME TO OPPOSE FILED involving Gilead Sciences, Inc.